Advanced Drug Delivery Reviews, ISSN 0169-409X, 09/2012, Volume 64, Issue 12, pp. 1277 - 1291
Over the past several decades, recombinant human bone morphogenetic proteins (rhBMPs) have been the most extensively studied and widely used osteoinductive...
rhBMPs | Regenerative medicine | Bone fracture | Bone tissue engineering | Drug delivery | Spinal surgery | Oral surgery | RhBMPs | PROTEIN-2/COMPRESSION RESISTANT MATRIX | GROWTH-FACTOR DELIVERY | LUMBAR SPINE FUSION | OP-1 PUTTY RHBMP-7 | BETA-TRICALCIUM PHOSPHATE | MESENCHYMAL STEM-CELLS | SYNTHETIC BIODEGRADABLE POLYMERS | ILIAC CREST AUTOGRAFT | PHARMACOLOGY & PHARMACY | OPEN TIBIAL FRACTURES | MARROW STROMAL CELLS | Recombinant Proteins - therapeutic use | Tissue Engineering - methods | United States | Humans | Bone Regeneration | Drug Approval | Recombinant Proteins - administration & dosage | Drug Delivery Systems | Tissue Scaffolds - chemistry | Animals | Bone Morphogenetic Protein 2 - administration & dosage | Bone Morphogenetic Protein 2 - therapeutic use | Bone and Bones - metabolism | Bone Morphogenetic Protein 7 - administration & dosage | Bone Morphogenetic Protein 7 - therapeutic use | United States Food and Drug Administration | Bone morphogenetic proteins | Usage | Fractures | Tissue engineering | Bone (long) | oral surgery | bone tissue engineering | regenerative medicine | bone fracture | spinal surgery | drug delivery
rhBMPs | Regenerative medicine | Bone fracture | Bone tissue engineering | Drug delivery | Spinal surgery | Oral surgery | RhBMPs | PROTEIN-2/COMPRESSION RESISTANT MATRIX | GROWTH-FACTOR DELIVERY | LUMBAR SPINE FUSION | OP-1 PUTTY RHBMP-7 | BETA-TRICALCIUM PHOSPHATE | MESENCHYMAL STEM-CELLS | SYNTHETIC BIODEGRADABLE POLYMERS | ILIAC CREST AUTOGRAFT | PHARMACOLOGY & PHARMACY | OPEN TIBIAL FRACTURES | MARROW STROMAL CELLS | Recombinant Proteins - therapeutic use | Tissue Engineering - methods | United States | Humans | Bone Regeneration | Drug Approval | Recombinant Proteins - administration & dosage | Drug Delivery Systems | Tissue Scaffolds - chemistry | Animals | Bone Morphogenetic Protein 2 - administration & dosage | Bone Morphogenetic Protein 2 - therapeutic use | Bone and Bones - metabolism | Bone Morphogenetic Protein 7 - administration & dosage | Bone Morphogenetic Protein 7 - therapeutic use | United States Food and Drug Administration | Bone morphogenetic proteins | Usage | Fractures | Tissue engineering | Bone (long) | oral surgery | bone tissue engineering | regenerative medicine | bone fracture | spinal surgery | drug delivery
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2010, Volume 6, Issue 6, p. CD006950
Background Delay in fracture healing is a complex clinical and economic issue for patients and health services. Objectives To assess the incremental...
MEDICINE, GENERAL & INTERNAL | DEFECTS | MANAGEMENT | HEALTH ECONOMICS | NONUNION | GUIDELINES | SHAFT | GRAFT | COMPLICATIONS | QUALITY-OF-LIFE | OPEN TIBIAL FRACTURES | Recombinant Proteins - therapeutic use | Humans | Fractures, Malunited - drug therapy | Fractures, Ununited - economics | Fractures, Ununited - drug therapy | Tibial Fractures - economics | Transforming Growth Factor beta - economics | Tibial Fractures - drug therapy | Fracture Healing - drug effects | Transforming Growth Factor beta - therapeutic use | Bone Morphogenetic Protein 7 - economics | Fracture Healing - physiology | Adult | Bone Morphogenetic Proteins - economics | Radius Fractures - economics | Bone Morphogenetic Protein 2 | Fractures, Malunited - economics | Fractures, Bone - economics | Recombinant Proteins - economics | Randomized Controlled Trials as Topic | Health Care Costs | Cost-Benefit Analysis | Bone Morphogenetic Proteins - therapeutic use | Radius Fractures - drug therapy | Bone Morphogenetic Protein 7 - therapeutic use | Fractures, Bone - drug therapy
MEDICINE, GENERAL & INTERNAL | DEFECTS | MANAGEMENT | HEALTH ECONOMICS | NONUNION | GUIDELINES | SHAFT | GRAFT | COMPLICATIONS | QUALITY-OF-LIFE | OPEN TIBIAL FRACTURES | Recombinant Proteins - therapeutic use | Humans | Fractures, Malunited - drug therapy | Fractures, Ununited - economics | Fractures, Ununited - drug therapy | Tibial Fractures - economics | Transforming Growth Factor beta - economics | Tibial Fractures - drug therapy | Fracture Healing - drug effects | Transforming Growth Factor beta - therapeutic use | Bone Morphogenetic Protein 7 - economics | Fracture Healing - physiology | Adult | Bone Morphogenetic Proteins - economics | Radius Fractures - economics | Bone Morphogenetic Protein 2 | Fractures, Malunited - economics | Fractures, Bone - economics | Recombinant Proteins - economics | Randomized Controlled Trials as Topic | Health Care Costs | Cost-Benefit Analysis | Bone Morphogenetic Proteins - therapeutic use | Radius Fractures - drug therapy | Bone Morphogenetic Protein 7 - therapeutic use | Fractures, Bone - drug therapy
Journal Article
International Orthopaedics, ISSN 0341-2695, 9/2011, Volume 35, Issue 9, pp. 1271 - 1280
This review evaluates the application of bone morphogenetic proteins (BMPs) in delayed bone repair, aiming at a broad audience from clinicians to scientists....
Medicine & Public Health | Orthopedics | GROWTH-FACTOR-BETA | IN-VITRO | SPINAL-FUSION | CLINICAL-APPLICATIONS | TIBIAL FRACTURES | OSTEOGENIC ACTIVITY | GENE-THERAPY | MOLECULAR ASPECTS | BMP-2 | ORTHOPEDICS | EXPRESSION | Bone Regeneration - drug effects | Bone Regeneration - physiology | Humans | Treatment Outcome | Clinical Trials as Topic | Bone Morphogenetic Protein 2 - economics | Bone Morphogenetic Protein 2 - adverse effects | Health Care Costs | Animals | Fracture Healing - drug effects | Bone Morphogenetic Protein 2 - therapeutic use | Fracture Healing - physiology | Bone Morphogenetic Protein 7 - therapeutic use | Fractures, Bone - drug therapy | Disease Models, Animal | Bone morphogenetic proteins | Usage | Fractures | Analysis | Antagonists | Reviews | Bone healing | Review
Medicine & Public Health | Orthopedics | GROWTH-FACTOR-BETA | IN-VITRO | SPINAL-FUSION | CLINICAL-APPLICATIONS | TIBIAL FRACTURES | OSTEOGENIC ACTIVITY | GENE-THERAPY | MOLECULAR ASPECTS | BMP-2 | ORTHOPEDICS | EXPRESSION | Bone Regeneration - drug effects | Bone Regeneration - physiology | Humans | Treatment Outcome | Clinical Trials as Topic | Bone Morphogenetic Protein 2 - economics | Bone Morphogenetic Protein 2 - adverse effects | Health Care Costs | Animals | Fracture Healing - drug effects | Bone Morphogenetic Protein 2 - therapeutic use | Fracture Healing - physiology | Bone Morphogenetic Protein 7 - therapeutic use | Fractures, Bone - drug therapy | Disease Models, Animal | Bone morphogenetic proteins | Usage | Fractures | Analysis | Antagonists | Reviews | Bone healing | Review
Journal Article
Biotechnology Letters, ISSN 0141-5492, 11/2009, Volume 31, Issue 12, pp. 1817 - 1824
Recombinant human bone morphogenetic proteins (rhBMPs) have been extensively investigated for developing therapeutic strategies aimed at the restoration and...
Bone morphogenetic proteins | Bone repair | Bone regeneration | Delivery systems | Craniofacial surgery | Orthopaedics | COLLAGEN | EFFICACY | DISTRACTION OSTEOGENESIS | TISSUE REGENERATION | RABBITS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CLINICAL-APPLICATIONS | GROWTH-FACTORS | IN-VIVO | SCAFFOLDS | RELEASE KINETICS | Recombinant Proteins - therapeutic use | Bone Morphogenetic Protein 2 - genetics | Bone Regeneration - physiology | Bone Diseases - therapy | Bone Morphogenetic Protein 2 - therapeutic use | Bone Morphogenetic Protein 7 - genetics | Humans | Orthopedic Procedures - methods | Recombinant Proteins - genetics | Craniofacial Abnormalities - therapy | Bone Morphogenetic Protein 7 - therapeutic use | Usage | Research | Recombinant proteins | Proteins | Biotechnology | Bones | Genetic recombination | Tissue engineering
Bone morphogenetic proteins | Bone repair | Bone regeneration | Delivery systems | Craniofacial surgery | Orthopaedics | COLLAGEN | EFFICACY | DISTRACTION OSTEOGENESIS | TISSUE REGENERATION | RABBITS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CLINICAL-APPLICATIONS | GROWTH-FACTORS | IN-VIVO | SCAFFOLDS | RELEASE KINETICS | Recombinant Proteins - therapeutic use | Bone Morphogenetic Protein 2 - genetics | Bone Regeneration - physiology | Bone Diseases - therapy | Bone Morphogenetic Protein 2 - therapeutic use | Bone Morphogenetic Protein 7 - genetics | Humans | Orthopedic Procedures - methods | Recombinant Proteins - genetics | Craniofacial Abnormalities - therapy | Bone Morphogenetic Protein 7 - therapeutic use | Usage | Research | Recombinant proteins | Proteins | Biotechnology | Bones | Genetic recombination | Tissue engineering
Journal Article
International Orthopaedics, ISSN 0341-2695, 3/2014, Volume 38, Issue 3, pp. 635 - 647
The purpose of this study was to revise the clinical use of commercial BMP2 (Infuse) and BMP7 (Osigraft) based bone devices and explore the mechanism of action...
Whole blood containing device | BMP2 | Medicine & Public Health | Bone regeneration | Orthopedics | Bone fracture | Commercial bone devices | OSTEOGROW | Bone morphogenetic protein 6 (BMP6) | BMP7 | IA RECEPTOR BMPRIA | GROWTH-FACTOR-BETA | SPINAL-FUSION | ARTICULAR-CARTILAGE | OSTEOBLAST-LINEAGE CELLS | OSTEOGENIC PROTEIN-1 | ORTHOPEDICS | LUMBAR INTERBODY FUSION | OSTEOCLAST DIFFERENTIATION | OPEN TIBIAL FRACTURES | RADIOGRAPHIC OUTCOMES | Bone Morphogenetic Protein 2 - pharmacology | Rabbits | Osteogenesis - physiology | Osteogenesis - drug effects | Rats | Biocompatible Materials - pharmacology | Bone Morphogenetic Protein 6 - pharmacology | Drug Delivery Systems | Mice, Knockout | Bone Morphogenetic Protein 6 - therapeutic use | Dose-Response Relationship, Drug | Animals | Bone Morphogenetic Protein 6 - administration & dosage | Bone Morphogenetic Protein 2 - therapeutic use | Fractures, Bone - physiopathology | Models, Animal | Biocompatible Materials - administration & dosage | Biocompatible Materials - therapeutic use | Mice | Wound Healing - physiology | Wound Healing - drug effects | Bone Morphogenetic Protein 7 - pharmacology | Bone Morphogenetic Protein 7 - therapeutic use | Fractures, Bone - drug therapy | Bone morphogenetic proteins | Usage | Fractures | Hematopoietic stem cells | Review
Whole blood containing device | BMP2 | Medicine & Public Health | Bone regeneration | Orthopedics | Bone fracture | Commercial bone devices | OSTEOGROW | Bone morphogenetic protein 6 (BMP6) | BMP7 | IA RECEPTOR BMPRIA | GROWTH-FACTOR-BETA | SPINAL-FUSION | ARTICULAR-CARTILAGE | OSTEOBLAST-LINEAGE CELLS | OSTEOGENIC PROTEIN-1 | ORTHOPEDICS | LUMBAR INTERBODY FUSION | OSTEOCLAST DIFFERENTIATION | OPEN TIBIAL FRACTURES | RADIOGRAPHIC OUTCOMES | Bone Morphogenetic Protein 2 - pharmacology | Rabbits | Osteogenesis - physiology | Osteogenesis - drug effects | Rats | Biocompatible Materials - pharmacology | Bone Morphogenetic Protein 6 - pharmacology | Drug Delivery Systems | Mice, Knockout | Bone Morphogenetic Protein 6 - therapeutic use | Dose-Response Relationship, Drug | Animals | Bone Morphogenetic Protein 6 - administration & dosage | Bone Morphogenetic Protein 2 - therapeutic use | Fractures, Bone - physiopathology | Models, Animal | Biocompatible Materials - administration & dosage | Biocompatible Materials - therapeutic use | Mice | Wound Healing - physiology | Wound Healing - drug effects | Bone Morphogenetic Protein 7 - pharmacology | Bone Morphogenetic Protein 7 - therapeutic use | Fractures, Bone - drug therapy | Bone morphogenetic proteins | Usage | Fractures | Hematopoietic stem cells | Review
Journal Article
Biotechnology Letters, ISSN 0141-5492, 11/2009, Volume 31, Issue 12, pp. 1825 - 1835
Localized and release-controlled delivery systems for the sustained expression of the biologic potency of rhBMPs are essential. A substantial number of...
Nanoparticles | Bone morphogenetic proteins | Controlled-release | Synthetic polymers | Bone regeneration | Biomaterials | GROWTH-FACTOR DELIVERY | DRUG-DELIVERY | GRAFT SUBSTITUTES | SYNTHETIC BIODEGRADABLE POLYMERS | ILIAC CREST AUTOGRAFT | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | BIOACTIVE MOLECULES | IN-VIVO | POSTEROLATERAL LUMBAR ARTHRODESIS | RADIOGRAPHIC OUTCOMES | Recombinant Proteins - therapeutic use | Bone Morphogenetic Protein 2 - genetics | Bone Regeneration - physiology | Bone Diseases - therapy | Bone Morphogenetic Protein 7 - genetics | Humans | Orthopedic Procedures - methods | Recombinant Proteins - genetics | Craniofacial Abnormalities - therapy | Recombinant Proteins - administration & dosage | Bone Morphogenetic Protein 2 - administration & dosage | Bone Morphogenetic Protein 2 - therapeutic use | Delayed-Action Preparations - therapeutic use | Bone Morphogenetic Protein 7 - administration & dosage | Bone Morphogenetic Protein 7 - therapeutic use | Research | Tissue engineering | Health aspects | Methods | Biotechnology | Bones | Biomedical materials | Orthopedics
Nanoparticles | Bone morphogenetic proteins | Controlled-release | Synthetic polymers | Bone regeneration | Biomaterials | GROWTH-FACTOR DELIVERY | DRUG-DELIVERY | GRAFT SUBSTITUTES | SYNTHETIC BIODEGRADABLE POLYMERS | ILIAC CREST AUTOGRAFT | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | BIOACTIVE MOLECULES | IN-VIVO | POSTEROLATERAL LUMBAR ARTHRODESIS | RADIOGRAPHIC OUTCOMES | Recombinant Proteins - therapeutic use | Bone Morphogenetic Protein 2 - genetics | Bone Regeneration - physiology | Bone Diseases - therapy | Bone Morphogenetic Protein 7 - genetics | Humans | Orthopedic Procedures - methods | Recombinant Proteins - genetics | Craniofacial Abnormalities - therapy | Recombinant Proteins - administration & dosage | Bone Morphogenetic Protein 2 - administration & dosage | Bone Morphogenetic Protein 2 - therapeutic use | Delayed-Action Preparations - therapeutic use | Bone Morphogenetic Protein 7 - administration & dosage | Bone Morphogenetic Protein 7 - therapeutic use | Research | Tissue engineering | Health aspects | Methods | Biotechnology | Bones | Biomedical materials | Orthopedics
Journal Article
Journal of Orthopaedic Research, ISSN 0736-0266, 01/2017, Volume 35, Issue 1, pp. 51 - 60
ABSTRACT Intervertebral disc (IVD) degeneration is the leading trigger of low back pain, which causes disability and leads to enormous healthcare toll...
BMP‐2/7 heterodimer | intervertebral disc | nucleus pulposus regeneration | whole organ culture | BMP-2/7 heterodimer | BONE MORPHOGENETIC PROTEIN-2 | RESTORATION | MODEL | HEIGHT | DEGENERATION | INJECTION | GROWTH-FACTORS | INTERVERTEBRAL DISC CELLS | ANNULUS FIBROSUS | ORTHOPEDICS | SCAFFOLD | Bone Morphogenetic Protein 2 - pharmacology | Immunohistochemistry | Hydrogels | Nucleus Pulposus - metabolism | Nucleus Pulposus - drug effects | Spectroscopy, Fourier Transform Infrared | Regeneration - drug effects | Animals | Bone Morphogenetic Protein 2 - therapeutic use | Cattle | Primary Cell Culture | Drug Evaluation, Preclinical | Intervertebral Disc Degeneration - drug therapy | Bone Morphogenetic Protein 7 - pharmacology | Bone Morphogenetic Protein 7 - therapeutic use | Fibrin | Biological products | Phosphatases | Analysis | Collagen | Bone morphogenetic proteins | Hyaluronic acid | Gene expression
BMP‐2/7 heterodimer | intervertebral disc | nucleus pulposus regeneration | whole organ culture | BMP-2/7 heterodimer | BONE MORPHOGENETIC PROTEIN-2 | RESTORATION | MODEL | HEIGHT | DEGENERATION | INJECTION | GROWTH-FACTORS | INTERVERTEBRAL DISC CELLS | ANNULUS FIBROSUS | ORTHOPEDICS | SCAFFOLD | Bone Morphogenetic Protein 2 - pharmacology | Immunohistochemistry | Hydrogels | Nucleus Pulposus - metabolism | Nucleus Pulposus - drug effects | Spectroscopy, Fourier Transform Infrared | Regeneration - drug effects | Animals | Bone Morphogenetic Protein 2 - therapeutic use | Cattle | Primary Cell Culture | Drug Evaluation, Preclinical | Intervertebral Disc Degeneration - drug therapy | Bone Morphogenetic Protein 7 - pharmacology | Bone Morphogenetic Protein 7 - therapeutic use | Fibrin | Biological products | Phosphatases | Analysis | Collagen | Bone morphogenetic proteins | Hyaluronic acid | Gene expression
Journal Article
Journal of Bone and Joint Surgery - American Volume, ISSN 0021-9355, 03/2016, Volume 98, Issue 6, p. e23
Journal Article
The Spine Journal, ISSN 1529-9430, 01/2018, Volume 18, Issue 1, pp. 139 - 146
Bone morphogenetic protein (BMP)-2/7 heterodimer is a stronger inducer of bone regeneration than individual homodimers. However, clinical application of its...
Bone induction | Inflammation | Bone morphogenetic protein | Magnetic resonance imaging | Micro-computed tomography | Heterodimer | SURGERY | IDENTIFICATION | CLINICAL NEUROLOGY | SPINAL-FUSION MODEL | ANTERIOR CERVICAL-SPINE | MORPHOGENETIC PROTEIN | RHBMP-2 | OSTEOGENIC PROTEIN-1 | COMPLICATIONS | RECEPTORS | ORTHOPEDICS | RODENT MODEL | Bone Morphogenetic Protein 2 - pharmacology | Tumor Necrosis Factor-alpha - metabolism | Bone Regeneration - drug effects | Tumor Necrosis Factor-alpha - genetics | Rats, Inbred Lew | Rats | Male | Interleukins - metabolism | Tissue Scaffolds - chemistry | Interleukins - genetics | Animals | Bone Morphogenetic Protein 2 - therapeutic use | Guided Tissue Regeneration - methods | Collagen - therapeutic use | Bone Morphogenetic Protein 7 - pharmacology | Bone Morphogenetic Protein 7 - therapeutic use
Bone induction | Inflammation | Bone morphogenetic protein | Magnetic resonance imaging | Micro-computed tomography | Heterodimer | SURGERY | IDENTIFICATION | CLINICAL NEUROLOGY | SPINAL-FUSION MODEL | ANTERIOR CERVICAL-SPINE | MORPHOGENETIC PROTEIN | RHBMP-2 | OSTEOGENIC PROTEIN-1 | COMPLICATIONS | RECEPTORS | ORTHOPEDICS | RODENT MODEL | Bone Morphogenetic Protein 2 - pharmacology | Tumor Necrosis Factor-alpha - metabolism | Bone Regeneration - drug effects | Tumor Necrosis Factor-alpha - genetics | Rats, Inbred Lew | Rats | Male | Interleukins - metabolism | Tissue Scaffolds - chemistry | Interleukins - genetics | Animals | Bone Morphogenetic Protein 2 - therapeutic use | Guided Tissue Regeneration - methods | Collagen - therapeutic use | Bone Morphogenetic Protein 7 - pharmacology | Bone Morphogenetic Protein 7 - therapeutic use
Journal Article